Advertisement
Advertisement
August 25, 2025
Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold Approved in Europe
August 25, 2025—Abbott announced it has received European CE Mark approval for the Esprit below-the-knee (BTK) everolimus-eluting resorbable scaffold system for the treatment of BTK peripheral artery disease (PAD).
The company noted that 2-year results from the LIFE-BTK trial demonstrated that the Esprit BTK system resulted in improved patient outcomes and 48% fewer repeat procedures compared to balloon angioplasty. The findings were presented at VIVA, the Vascular InterVentional Advances meeting, in November 2024.
Professor Dierk Scheinert, MD, with the University Hospital Leipzig in Leipzig, Germany, commented on the device in Abbott’s press release.
“For too long, patients with severe PAD below the knee have had limited treatment options and were often faced with potential amputations,” commented Prof. Scheinert. “With CE Mark, the Esprit BTK system offers a resorbable scaffold backed by strong data and proven superiority over balloon angioplasty—giving physicians a novel, innovative tool to treat the most severe forms of PAD more effectively and improve patient outcomes across Europe.”
In April 2024, the company announced that the Esprit BTK system received FDA approval.
Advertisement
Advertisement
